Compare Stocks: HOWL, TELO, ATRA, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.61 +1.9%	$9.53	$3.92 ▼ $19.15	$77.58M	0.12	779,101 shs	45,318 shs
HOWL Werewolf Therapeutics	$0.38 -3.8%	$0.38	$0.27 ▼ $2.38	$18.57M	0.29	567,241 shs	156,511 shs
SERA Sera Prognostics	$2.01 -2.9%	$2.00	$1.56 ▼ $3.95	$78.71M	0.96	53,071 shs	30,860 shs
TELO Telomir Pharmaceuticals	$1.17 +0.9%	$1.23	$0.89 ▼ $2.09	$80.47M	-0.24	128,368 shs	36,830 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	+0.84%	-13.42%	-3.76%	-22.83%
HOWL Werewolf Therapeutics	0.00%	+12.46%	-1.46%	-39.88%	-66.06%
SERA Sera Prognostics	0.00%	+1.47%	+5.08%	+19.65%	-16.53%
TELO Telomir Pharmaceuticals	0.00%	-4.13%	-5.69%	-10.08%	-25.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.61 +1.9%	$9.53	$3.92 ▼ $19.15	$77.58M	0.12	779,101 shs	45,318 shs
HOWL Werewolf Therapeutics	$0.38 -3.8%	$0.38	$0.27 ▼ $2.38	$18.57M	0.29	567,241 shs	156,511 shs
SERA Sera Prognostics	$2.01 -2.9%	$2.00	$1.56 ▼ $3.95	$78.71M	0.96	53,071 shs	30,860 shs
TELO Telomir Pharmaceuticals	$1.17 +0.9%	$1.23	$0.89 ▼ $2.09	$80.47M	-0.24	128,368 shs	36,830 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	+0.84%	-13.42%	-3.76%	-22.83%
HOWL Werewolf Therapeutics	0.00%	+12.46%	-1.46%	-39.88%	-66.06%
SERA Sera Prognostics	0.00%	+1.47%	+5.08%	+19.65%	-16.53%
TELO Telomir Pharmaceuticals	0.00%	-4.13%	-5.69%	-10.08%	-25.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	10.34% Upside
HOWL Werewolf Therapeutics	2.14	Hold	$3.75	881.68% Upside
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	173.63% Upside
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest HOWL, TELO, ATRA, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/17/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/4/2026	SERA Sera Prognostics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/18/2026	ATRA Atara Biotherapeutics	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$23.14M	3.35	$4.95 per share	1.74	($5.34) per share	-1.61
HOWL Werewolf Therapeutics	$1.88M	9.88	N/A	N/A	$0.51 per share	0.75
SERA Sera Prognostics	$80K	983.90	N/A	N/A	$1.94 per share	1.04
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$0.67	N/A	6.15	N/A	-40.91%	-79.12%	-35.29%	8/10/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	8/13/2026 (Estimated)
SERA Sera Prognostics	-$31.93M	-$0.65	N/A	N/A	N/A	-56,385.97%	-41.02%	-30.95%	8/12/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.29	N/A	N/A	N/A	N/A	-201.23%	-172.71%	9/2/2026 (Estimated)

Latest HOWL, TELO, ATRA, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	TELO Telomir Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.14	N/A	N/A	N/A	$0.07 million	N/A
8/10/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	N/A	N/A	N/A	$0.55 million	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million
5/14/2026	Q1 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.03	+$0.04	-$0.03	N/A	N/A
5/12/2026	Q1 2026	ATRA Atara Biotherapeutics	-$0.3295	-$0.29	+$0.0395	-$0.29	$2.90 million	$0.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	2.16	2.16
HOWL Werewolf Therapeutics	N/A	2.91	2.91
SERA Sera Prognostics	N/A	2.12	2.12
TELO Telomir Pharmaceuticals	N/A	7.00	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
HOWL Werewolf Therapeutics	64.84%
SERA Sera Prognostics	54.64%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
HOWL Werewolf Therapeutics	23.60%
SERA Sera Prognostics	11.30%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
SERA Sera Prognostics	120	39.16 million	34.73 million	Optionable
TELO Telomir Pharmaceuticals	1	68.78 million	57.52 million	N/A

HOWL, TELO, ATRA, and SERA Headlines

Recent News About These Companies

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10 at 8:51 AM | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10 at 8:30 AM | quiverquant.comQ

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 17.2% - Here's Why

July 21, 2026 | marketbeat.com

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026 | usatoday.com

Telomir Pharmaceuticals Inc.

April 2, 2026 | barrons.com

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

April 2, 2026 | msn.com

Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance

March 31, 2026 | tipranks.com

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

March 31, 2026 | accessnewswire.comA

Telomir Shareholders Approve Equity Plan and Bylaw Changes

March 27, 2026 | tipranks.com

Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines

February 21, 2026 | aktiencheck.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, TELO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.61 +0.16 (+1.89%)

As of 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Werewolf Therapeutics NASDAQ:HOWL

$0.38 -0.02 (-3.80%)

As of 04:00 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Sera Prognostics NASDAQ:SERA

$2.01 -0.06 (-2.90%)

As of 04:00 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Telomir Pharmaceuticals NASDAQ:TELO

$1.17 +0.01 (+0.86%)

As of 04:00 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, TELO, ATRA, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, TELO, ATRA, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, TELO, ATRA, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, TELO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Werewolf Therapeutics NASDAQ:HOWL

Sera Prognostics NASDAQ:SERA

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, TELO, ATRA, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, TELO, ATRA, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, TELO, ATRA, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, TELO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Werewolf Therapeutics NASDAQ:HOWL

Sera Prognostics NASDAQ:SERA

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools